CA2781914A1 - Substituted triazolopyridines - Google Patents

Substituted triazolopyridines Download PDF

Info

Publication number
CA2781914A1
CA2781914A1 CA2781914A CA2781914A CA2781914A1 CA 2781914 A1 CA2781914 A1 CA 2781914A1 CA 2781914 A CA2781914 A CA 2781914A CA 2781914 A CA2781914 A CA 2781914A CA 2781914 A1 CA2781914 A1 CA 2781914A1
Authority
CA
Canada
Prior art keywords
alkyl
alkoxy
halo
nr8r7
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2781914A
Other languages
English (en)
French (fr)
Inventor
Volker Schulze
Marcus Koppitz
Dirk Kosemund
Benjamin Bader
Philip Lienau
Hans Briem
Simon Holton
Gerhard Siemeister
Stefan Prechtl
Antje Margret Wengner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2781914A1 publication Critical patent/CA2781914A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2781914A 2009-11-30 2010-11-17 Substituted triazolopyridines Abandoned CA2781914A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075527A EP2343294A1 (en) 2009-11-30 2009-11-30 Substituted triazolopyridines
EP09075527.3 2009-11-30
PCT/EP2010/006993 WO2011063907A1 (en) 2009-11-30 2010-11-17 Substituted triazolopyridines

Publications (1)

Publication Number Publication Date
CA2781914A1 true CA2781914A1 (en) 2011-06-03

Family

ID=42026745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2781914A Abandoned CA2781914A1 (en) 2009-11-30 2010-11-17 Substituted triazolopyridines

Country Status (7)

Country Link
US (1) US8551980B2 (enExample)
EP (2) EP2343294A1 (enExample)
JP (1) JP5805652B2 (enExample)
CN (1) CN102858768B (enExample)
CA (1) CA2781914A1 (enExample)
ES (1) ES2439776T3 (enExample)
WO (1) WO2011063907A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP5824065B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CN103370322B (zh) 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
EP2651948A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
CN103429592A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651947B1 (en) 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103582632B (zh) 2011-03-31 2015-08-19 拜耳知识产权有限责任公司 取代的苯并咪唑
US20140255392A1 (en) 2011-04-06 2014-09-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
NZ703020A (en) * 2012-07-10 2017-08-25 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
MA38656A1 (fr) * 2013-06-11 2018-05-31 Bayer Pharma AG Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH0690447B2 (ja) 1986-09-12 1994-11-14 コニカ株式会社 ハロゲン化銀写真感光材料
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
WO2003000659A1 (en) 2001-06-26 2003-01-03 Nissan Chemical Industries, Ltd. Heterocycloiminophenyl compounds and fungicides and insecticides for agricultural and horticultural use
CA2498000C (en) 2002-09-11 2015-01-20 Genentech, Inc. Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
JP2007514757A (ja) * 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
EP1978973B1 (en) 2005-12-27 2011-11-16 Genentech, Inc. Use hedgehog kinase antagonists to inhibit hedgehog signaling and to treat cancer
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
TW200831673A (en) 2006-12-13 2008-08-01 Oncotherapy Science Inc TTK as tumor marker and therapeutic target for lung cancer
KR20100049073A (ko) * 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
JP2010536841A (ja) * 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
JP2010536917A (ja) 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
SG186040A1 (en) 2007-11-27 2012-12-28 Cellzome Ltd Amino triazoles as pi3k inhibitors
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
RU2560153C2 (ru) 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
NZ593595A (en) 2008-12-19 2013-07-26 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
KR20110116160A (ko) 2009-02-13 2011-10-25 포비어 파마수티칼스 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-ａ〕피리딘
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
US8367830B2 (en) 2009-05-20 2013-02-05 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
MX2011012961A (es) 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
WO2011137313A1 (en) 2010-04-30 2011-11-03 Bristol-Myers Squibb Company Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
JP5911476B2 (ja) 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica

Also Published As

Publication number Publication date
WO2011063907A1 (en) 2011-06-03
ES2439776T3 (es) 2014-01-24
CN102858768A (zh) 2013-01-02
US20120328611A1 (en) 2012-12-27
EP2343294A1 (en) 2011-07-13
JP2013512263A (ja) 2013-04-11
CN102858768B (zh) 2016-01-20
JP5805652B2 (ja) 2015-11-04
EP2507233B1 (en) 2013-11-06
US8551980B2 (en) 2013-10-08
EP2507233A1 (en) 2012-10-10
HK1180333A1 (zh) 2013-10-18

Similar Documents

Publication Publication Date Title
EP2507233B1 (en) Substituted triazolopyridines
US9676766B2 (en) Triazolopyridines
EP2507236B1 (en) Triazolopyridine derivates
US9284317B2 (en) Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
EP2651946B1 (en) 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9468642B2 (en) Imidazopyrazines
AU2012244859B2 (en) Triazolopyridines
WO2012080236A1 (en) 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2802629A1 (en) Substituted triazolopyridines
US9212184B2 (en) 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors
WO2012160029A1 (en) Substituted triazolopyridines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151019

FZDE Discontinued

Effective date: 20181119